Home › Research › Tau biomarkers
[Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]
Urakami K, Nakashima K.. Rinsho shinkeigaku = Clinical neurology, 2002-11-01
Topic: Brain proteins, microglia and lab models
The diagnostic significance of tau proteins in cerebrospinal fluids (CSF) has been described in many cases of dementia of Alzheimer type (AD). However, in patients with other diseases showing neurofibrillary tangles (NFT) similar to those in AD, tau proteins in cerebrospinal fluids have not been rigorously investigated. In particular, differentiating corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) is clinically and pathologically difficult, and a useful biochemical marker to discriminate these two diseases has been a subjects of clinical interest.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Urakami, K., & Nakashima, K. (2002). [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]. Rinsho shinkeigaku = Clinical neurology.
Vancouver
Urakami K, Nakashima K. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]. Rinsho shinkeigaku = Clinical neurology. 2002. PMID: 12784694.
BibTeX
@article{urakami2002-12784694,
author = {Urakami, K. and Nakashima, K.},
title = {{[Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]}},
journal = {Rinsho shinkeigaku = Clinical neurology},
year = {2002},
pmid = {12784694}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, in patients with other diseases showing neurofibrillary tangles (NFT) similar to those in AD, tau proteins in cerebrospinal fluids have not been rigorously investigated.
- In particular, differentiating corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) is clinically and pathologically difficult, and a useful biochemical marker to discriminate these two diseases has been a subjects of clinical interest.
- Therefore, we examined the usefulness of CSF tau and amyloid beta (A beta) proteins for the differentiation between CBD and PSP.
- CSF total tau (t-tau) and A beta proteins were measured with the sandwich ELISA method (Innogenetics, Belgium).
Why it matters
This study examined whether cerebrospinal fluid tau and amyloid beta markers could help tell apart corticobasal degeneration and progressive supranuclear palsy, conditions that are clinically and pathologically difficult to distinguish. It is a diagnostic marker study and does not test any treatment, cure, or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 26/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record and impact for its field and year, so those were left out: it earned 23 of the 90 points we could judge it on, which is 26 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Rinsho shinkeigaku = Clinical neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Kenji Nakashima: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Tottori University: institution h-index 304 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12784694) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 90 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 23 of the 90 points we could judge it on is 26 out of 100. |
| Total | 26 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related studies in Tau biomarkers
Also tagged “bodies”
1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.